A novel therapeutic giving cancer patients new hope.
Our novel therapeutic is focused on improving the effectiveness of cancer treatments and quality of life for the patients that receive them.
Truly novel.
Truly important.
We are on a mission to improve therapeutic outcomes for cancer patients with GP-2250, a tumor-cell selective agent with a truly novel mechanism of action.

Our Science
Disrupting cancer cell metabolism.
Our unique and patent-pending mechanism of action targets the primary mechanism of cancer cell energy production to disrupt mitochondrial integrity and bring about cancer cell death.
Focused on what matters most.
While our clinical-stage asset demonstrates broad potential in preclinical research across cancers and therapeutic applications, we have chosen to first focus on pancreatic cancer—a condition with a clear unmet need. Early clinical experience is promising.

The Latest
Publications
Metabolism-based GP-2250 in combination with gemcitabine as a novel approach to pancreatic cancer: A mouse xenograft study- in vitro and in vivo. MBC Cancer
2017, 17, 1-13. DOI: 10.1CO Annual Meetings 2020, Chicago (Abstract: Journal of Clinical Oncology 38, no. 15_suppl. DOI: 10.1200/JCO.2020.38.15_suppl.e16750
C. Braumann, M. Buchholz, B. Majchrzak – Stiller, S. Hahn, W. Uhl, A. Kasi, T. Mueller.
Pancreatic Tumor Remission in PDX-Models by Treatment with Gemcitabine in Combination with the Oxathiazine GP-2250 promising anti-neoplastic agent in malignant pancreatic carcinoma- in vitro and in vivo. MBC Cancer
German Cancer Congress, February 2020, Berlin, Germany (Abstract: Oncology Res Treat 2020; 43 (supply 1): 1-265, abstract 455, page 58 DOI: 10.1159/000506491)
B. Majchrzak-Stiller, M. Buchholz, S. Hahn, C. Braumann, W. Uhl.